Sales of the flu tx market increased due to the endemic

0.5 billion → 11.5 billion

In the first half of the year, outpatient Rxs reached 11.5 billion won, surpassing 10 billion won in 4 years

The prescription market disappears during the corona epidemic

In the first half of the year, the outpatient prescription market for flu treatment exceeded 10 billion won in four years.

 

As the number of flu patients surged after the end of the Corona 19 pandemic, the flu treatment market, which had disappeared over the past three years, expanded significantly.

 

According to UBIST, a drug research institute on the 5th, the outpatient prescription amount for influenza (flu) treatment in the first half of last year was recorded at 11.5 billion won.

 

It fell short of 100 million won in the first half of last year but soared more than 200 times in one year.

 

Quarterly outpatient Rx amount of flu treatment (unit: 100 million won, source: UBIST)

In the first and second quarters of last year, the flu treatment market size was only 40 million won and 4 million won, respectively.

 

It rose sharply to 5.1 billion won in the first and second quarters of this year.

 

It is the first time in four years since 2019 that the prescription of flu treatment in the first half of the year exceeded 10 billion won.

 

After recording 8.2 billion won in prescriptions in the first quarter of 2020, the flu treatment market virtually disappeared by the third quarter of last year.

 

After the spread of COVID-19 in earnest, the outbreak of infectious diseases has significantly decreased due to strengthened personal hygiene management such as washing hands and wearing masks.

 

According to the KDCA, the number of suspected flu patients per 1,000 outpatients recorded at 6.3 in the 9th week, the first week of March 2020, and has never exceeded 5 until August of last year.

 

This means that there has not been a single outbreak of the flu in 2 years and 6 months.

 

Influenza tx recorded 8.2 billion won in prescriptions in the first quarter of 2020 and virtually disappeared by the third quarter of last year, but started to rebound with 10.4 billion won in the fourth quarter of last year.

 

From the beginning of this year to last June, the number of flu patients exceeded the epidemic standard.

 

The number of suspected influenza patients per 1,000 outpatients dropped from 52.5 in the first week to 11.7 in March.

 

However, since April, the number of suspected flu cases has risen again.

 

For six consecutive weeks from the 17th week of the fourth week of April to the 22nd week of the last week of May, the number of suspected influenza patients per 1,000 outpatients was more than 20.

 

It is a level that significantly exceeds the flu prevalence standard of 4.9 set by the KDCA.

 

In the first half of last year, the prescription market for oseltamivir ingredients was limited to 40 million won, but in the first half of this year, it expanded 191 times to 7.9 billion won.

 

Oseltamivir is the main active ingredient in Tamiflu.

 

The size of the prescription market for Oseltamivir never exceeded 100 million won until the third quarter of last year after recording 6.6 billion won in the first quarter of 2020.

 

However, it succeeded in rebounding to 8.5 billion won in the fourth quarter of last year and continued its growth this year.

 

In the first half of last year, prescriptions for Tamiflu were only 30 million won, but this increased to 5.7 billion won in one year.